MedTrace Logo

Impact of a MVM to Support Biomarkers Associated With Conception and Pregnancy in Healthy Women.

NCT06505408 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-06-06

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate the effects multivitamin (MVM) on blood biomarkers that are associated with healthy pregnancy and conception in adult women. The main question it aims to answer is:

Is there a significant change in blood biomarkers from baseline (week 0) to end of intervention (week 12) in healthy women consuming multivitamin compared to participants consuming the placebo product?

Participants will:

Take drug MVM or a placebo every day for 12 weeks Visit the clinic at baseline and 12 weeks for serum blood draws and measurements Complete a series of surveys at baseline and 12 weeks

Conditions

  • Healthy Adult Women of Child Bearing Age

Interventions

DIETARY_SUPPLEMENT

Multivitamin

4 capsules of Perelel Health Conception Support Multivitamin Pack (consisting of vitamins, minerals, and omega ingredients) consumed daily for 12 weeks

DIETARY_SUPPLEMENT

Placebo

4 placebo capsules consumed daily for 12 weeks

Sponsors & Collaborators

  • Perelel Inc.

    lead INDUSTRY

Principal Investigators

  • Timothy Dinan, MD, PHD · Atlantia Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-02
Primary Completion
2025-01-20
Completion
2025-01-20

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06505408 on ClinicalTrials.gov